Here we describe how the combination of MS-based (phospho)proteomics with literature-derived signaling networks may help to identify new therapeutic targets to revert the chemoresistance of FLT3-dependent acute myeloid leukemia. This evidence concerns the gene FLT3 and acute myeloid leukemia.